Acreozast

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530027

CAS#: 123548-56-1

Description: Acreozast is a histamine release inhibitor potentially for the treatment of asthma and atopic dermatitis.

Chemical Structure

img
Acreozast
CAS# 123548-56-1
Instruction

Theoretical Analysis

MedKoo Cat#: 530027
Name: Acreozast
CAS#: 123548-56-1
Chemical Formula: C15H14ClN3O6
Exact Mass: 367.06
Molecular Weight: 367.740
Elemental Analysis: C, 48.99; H, 3.84; Cl, 9.64; N, 11.43; O, 26.10

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: TYB-2285; TYB2285; TYB 2285

IUPAC/Chemical Name: ((2-chloro-5-cyano-1,3-phenylene)bis(azanediyl))bis(2-oxoethane-2,1-diyl) diacetate

InChi Key: VNVBCWREJHKWSG-UHFFFAOYSA-N

InChi Code: InChI=1S/C15H14ClN3O6/c1-8(20)24-6-13(22)18-11-3-10(5-17)4-12(15(11)16)19-14(23)7-25-9(2)21/h3-4H,6-7H2,1-2H3,(H,18,22)(H,19,23)

SMILES Code: N#CC1=CC(NC(COC(C)=O)=O)=C(Cl)C(NC(COC(C)=O)=O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 367.74 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Tohda Y, Muraki M, Kubo H, Nakajima S, Fukuoka M, Watanabe A. Effect of TYB-2285 on early and late bronchial responses and airway hyperreactivity in actively sensitized guinea pigs. Gen Pharmacol. 1998 Aug;31(2):323-8. PubMed PMID: 9688481.

2: Abraham WM, Ahmed A, Cortes A, Sielczak M, Wantanabe A. Effect of TYB-2285 on antigen-induced airway responses in sheep. Pulm Pharmacol. 1996 Feb;9(1):49-58. PubMed PMID: 8843510.

3: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J. Effect of TYB-2285 on peritoneal anaphylaxis in passively sensitized rats. Gen Pharmacol. 1998 Aug;31(2):313-7. PubMed PMID: 9688479.

4: Tominaga T, Watanbe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on antigen-induced accumulation of eosinophils into the peritoneal cavity of rats sensitized with Ascaris suum extract. Gen Pharmacol. 1997 Mar;28(3):411-4. PubMed PMID: 9068982.

5: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on lung anaphylaxis in actively sensitized rats. Gen Pharmacol. 1997 Feb;28(2):305-9. PubMed PMID: 9013209.

6: Tominaga T, Watanabe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. The effects of TYB-2285 and its metabolites on lymphocyte responses in vitro. Gen Pharmacol. 1997 Sep;29(3):473-5. PubMed PMID: 9378259.

7: Kou K, Hayashi M, Nakajima T, Yoshizawa I, Kawano Y, Shikishima Y, Noma T. [Immunomodulation by TYB-2285 of Dermatophagoides farinae (Df) antigen-induced IFN-gamma and IL-4 production in lymphocytes from children with bronchial asthma]. Arerugi. 1997 Jun;46(6):502-10. Japanese. PubMed PMID: 9277001.

8: Watanabe A, Tominaga T, Shutoh H, Hayashi H, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effect of TYB-2285 on passive cutaneous anaphylaxis in rats. Gen Pharmacol. 1997 Feb;28(2):311-5. PubMed PMID: 9013210.

9: Tominaga T, Watanabe A, Tsuji J, Koda A, Nagai H, Kumazawa Y, Shimada H. Effects of TYB-2285 on the accumulation of eosinophils in the airway induced by antigen exposure in actively sensitized brown Norway rats. Gen Pharmacol. 1997 Feb;28(2):301-3. PubMed PMID: 9013208.

10: Ban M, Taguchi H, Katsushima T, Takahashi M, Shinoda K, Watanabe A, Tominaga T. Novel antiallergic and antiinflammatory agents. Part II: Synthesis and pharmacology of TYB-2285 and its related compounds. Bioorg Med Chem. 1998 Jul;6(7):1077-87. PubMed PMID: 9730245.

11: Muraki M, Tohda Y, Sugihara R, Nagasaka Y, Nakajima S. The effect of TYB-2285 on dual phase bronchoconstriction and airway hypersensitivity in guinea-pigs actively sensitized with ovalbumin. J Pharm Pharmacol. 1994 Nov;46(11):883-6. PubMed PMID: 7897592.

12: Tominaga T, Watanabe A, Hayashi H, Yanagihara Y, Koda A. Effect of TYB-2285 on histamine release from human basophils in the presence/absence of IL-3. Gen Pharmacol. 1993 Mar;24(2):345-8. PubMed PMID: 7683300.

13: Watanabe A, Tominaga T, Hayashi H, Yanagihara Y, Koda A. Effect of TYB-2285 on antigen-induced histamine release from mouse bone marrow-derived persisting cells (P-cells) primed with interleukin-3-containing conditioned medium (IL3-CM). Gen Pharmacol. 1993 Sep;24(5):1207-11. PubMed PMID: 7505757.

14: Tanimukai T, Ihaku D, Matsuyama T. [Role of adhesion molecules (VLA-4) in the asthmatic response to allergens]. Nihon Kyobu Shikkan Gakkai Zasshi. 1995 Nov;33(11):1240-9. Japanese. PubMed PMID: 8583716.